CoChat

Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography

Open access

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Light liquid paraffin (pharmaceutical grade mineral oil) has been used as a placebo in clinical trials of icosapent ethyl including MARINE, ANCHOR, and REDUCE-IT. Pharmaceutical grade mineral oil (distinct from technical/industrial or food grade mineral oils) was chosen as a suitable placebo to mimic the consistency, colour, and odourless properties of icosapent ethyl capsules. Since the results of REDUCE-IT, a few have raised questions regarding possible biological activity of mineral oil placebo due to small changes in some cardiac biomarkers including lipid levels and inflammatory markers in placebo arm patients, asking whether the mineral oil utilized in placebo capsules was physiologically inert or not.1 Mineral oil has been utilized in humans as a laxative for decades (typically in doses of 15–45 g/day), and the general safety has been inferred from clinical utilization. The ∼2 g twice per day of light liquid mineral oil taken by placebo group patients in clinical trials equates to less than a teaspoon per day. EVAPORATE is an ongoing randomized, placebo-controlled trial that evaluates the effect of icosapent ethyl 4 g daily in statin-treated patients with elevated triglycerides on coronary plaque progression by coronary computed tomography angiography (coronary CTA) compared with mineral oil placebo to provide important imaging-derived mechanistic information that can add insight to clinical outcomes from REDUCE-IT.2 Coronary plaque volumes, including total plaque and total non-calcified plaque derived by coronary CTA, have been measured and are known to be associated with myocardial ischaemia and adverse cardiac outcomes.3–5 In the present observational study, we sought to compare differences in progression of total plaque and total non-calcified plaque volumes on coronary CTA in mineral oil placebo patients from EVAPORATE vs. the non-mineral oil placebo arm from another randomized clinical trial, Garlic 5.6 We hypothesized that progression of total plaque and total non-calcified plaque volumes on coronary CTA is independent of consumption of mineral oil placebo capsules. The study design and rationale for EVAPORATE and Garlic 5 have been published previously.2,6 Eligible patients in EVAPORATE had known coronary atherosclerosis, elevated triglycerides (200–499 mg/dL), and low-density lipoprotein levels (LDL-C) ≤115 mg/dL while on statins. In Garlic 5, to be eligible, participants had coronary artery calcium scores >20 and known history of diabetes mellitus (DM). We acquired coronary CTA scans for evaluation of coronary plaque volume at baseline and at 12 months in Garlic 5 subjects and at baseline and at 9 months in EVAPORATE subjects. We performed quantitative plaque assessment using semi-automated plaque analysis software (QAngioCT Research Edition Version 2.0.5; Medis Medical Imaging Systems).7 Pharmaceutical grade mineral oil placebo used in EVAPORATE consisted of a purified liquid mixture of straight-chain saturated hydrocarbons that met the pharmaceutical compendial requirements of the US National Formulary (NF) for light mineral oil and of the European Pharmacopoeia (Ph. Eur.) for light liquid paraffin oil.8,9 The total daily dose of mineral oil placebo was four 1 g soft gelatine capsules, with two capsules taken twice daily with meals. The material does not contain any functional groups and is virtually free of all aromatic hydrocarbons and unsaturated hydrocarbons, making it chemically inert and allowing for minimal absorption. The composition of physiologically inert placebo powder (P-31) in Garlic 5 includes (per 100 mg) microcrystalline cellulose: 89.83 mg, hydroxypropyl cellulose: 10.07 mg, and caramel: 0.10 mg. The analysis of covariance test was used to examine rates of progression between the groups. The final model was adjusted for baseline plaque volume, age, sex, diabetes status, baseline triglyceride levels, and statin use. Total plaque and total non-calcified plaque volumes were log transformed to achieve a normal distribution. A P-value of <0.05 was considered significant. SAS software (version 9.4) was used for analyses. Mean [standard deviation (SD)] age of participants (n = 60) was 59 (9.9) years and 66% were male. A total of 28 participants from the Garlic 5 placebo arm and 32 participants from the EVAPORATE placebo arm were analysed. Participants had mean follow-up of 10.8 months. Baseline characteristics of the cohorts are listed in Table 1. There were no significant differences in major clinical characteristics including age, body mass index, hypertension, levels of LDL, total cholesterol, high-sensitivity C-reactive protein (hsCRP), or use of medications, including aspirin and statins. Due to eligibility criteria of the trials, the Garlic 5 placebo cohort was more likely to have diabetes and take diabetes medications, while the EVAPORATE placebo cohort was more likely to have high triglycerides. Baseline characteristics BMI, body mass index. Independent t-test. χ2 test.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cvr/cvz329

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Analysis of covariance for log adjusted total plaque volume (mm3). Adjusted for age, sex, baseline plaque volume, baseline triglycerides, diabetes, and statin use.
Figure 1 Analysis of covariance for log adjusted total plaque volume (mm3). Adjusted for age, sex, baseline plaque volume, baseline triglycerides, diabetes, and statin use.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 42

Metadata

Authors
Lakshmanan, S., Shekar, C., Kinninger, A., Dahal, S., Onuegbu, A., Cai, A. N., Hamal, S., Birudaraju, D., Roy, S. K., Nelson, J. R., Budoff, M. J., & Bhatt, D. L.
Affiliations
  • The Lundquist Institute (US)
  • University of Arizona College of Medicine- Phoenix (US)
  • Department of Cardiology, California Cardiovascular Institute, Fresno, CA, USA
  • Brigham and Women's Hospital (US)
Corresponding author
  • Budoff, Matthew J
  • Bhatt, Deepak L
Venue
Cardiovascular Research
Published
2019-12-11
Volume
116
Issue
3
Pages
479-482
ISSN
  • 0008-6363 (ISSN-L)
  • 1755-3245
OpenAlex
W2995193460
Cited by
42
References
13
Citations by year
2026: 1 · 2025: 1 · 2024: 3 · 2023: 7 · 2022: 10 · 2021: 11 · 2020: 8
FWCI
4.79
Type
journal article
Language
en
Open access
Locations
  • Cardiovascular Research (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
EVAPORATE
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords
icosapent ethyl, coronary plaque progression, coronary CT angiography, non-calcified plaque, triglyceride elevation, statin-treated patients, coronary artery disease, REDUCE-IT trial
MeSH terms
Computed Tomography Angiography, Aged, Coronary Artery Disease, Coronary Vessels, Female, Humans, Male, Middle Aged, Mineral Oil, Placebos, Predictive Value of Tests, Time Factors, Randomized Controlled Trials as Topic, Coronary Angiography, Disease Progression, Plaque, Atherosclerotic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography. https://app.cochat.ai/papers/10.1093/cvr/cvz329
The paper
Lakshmanan, S., Shekar, C., Kinninger, A., Dahal, S., Onuegbu, A., Cai, A. N., Hamal, S., Birudaraju, D., Roy, S. K., Nelson, J. R., Budoff, M. J., & Bhatt, D. L. (2020). Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography. Cardiovascular Research. https://doi.org/10.1093/cvr/cvz329

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.